What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?

References

• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39
   PubMed Web of Science ®Google Scholar
• Gatto M, Zen M, Ghirardello A, et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013;12:523-36
   PubMed Web of Science ®Google Scholar
• Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365:2110-21
   PubMed Web of Science ®Google Scholar
• Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-30
   PubMed Web of Science ®Google Scholar
• Yung R, Powers D, Johnson K, et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996;97:2866-71
   PubMed Web of Science ®Google Scholar
• James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019-26
   PubMed Web of Science ®Google Scholar
• Thanou A, Merrill JT. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. Nat Rev Rheumatol 2014;10:23-34
   PubMed Web of Science ®Google Scholar
• Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004;13:391-7
   PubMed Web of Science ®Google Scholar
• Fernandez DR, Perl A. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? Discov Med 2010;9:173-8
   PubMedGoogle Scholar
• Lai ZW, Borsuk R, Shadakshari A. mTOR activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus eryhthematosus. J Immunol 2013;191:2236-46
   PubMed Web of Science ®Google Scholar
• Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011;11:131-42
   PubMed Web of Science ®Google Scholar
• Bosma A, Abdel-Gadir A, Isenberg DA, et al. Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. Immunity 2012;36:477-90
   PubMed Web of Science ®Google Scholar
• Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res 2011;31:887-92
   PubMed Web of Science ®Google Scholar
• Mathian A, Weinberg A, Gallegos M, et al. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005;174:2499-506
   PubMed Web of Science ®Google Scholar
• Van Houten N, Budd RC. Accelerated programmed cell death of MRL-lpr/lpr T lymphocytes. J Immunol 1992;149:2513-17
   PubMed Web of Science ®Google Scholar
• Herrmann M, Voll RE, Zolle OM, et al. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1241-50
   PubMed Web of Science ®Google Scholar
• Mannik M, Merrill CE, Stamps LD, et al. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. 2003;30:1495-504
   Google Scholar
• Nowling TK, Gilkeson GS. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther 2011;13:250
   PubMed Web of Science ®Google Scholar
• Norris DA. Pathomechanisms of photosensitive lupus erythematosus. J Invest Dermatol 1993;100:58s-68s
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol 2010;6:358-67
   PubMed Web of Science ®Google Scholar
• Al-Homood IA. Thrombosis in systemic lupus erythematosus: a review article. ISRN Rheumatol 2012;12:428269
   Google Scholar
• Kivity S, Agmon-Levin N, Zandman-Goddard G, et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med 2015;13:43
   PubMed Web of Science ®Google Scholar
• Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2002;16:847-58
   PubMed Web of Science ®Google Scholar
• Lisnevskaia L, Murphy G, Isenberg DA. Systemic lupus erythematosus. The Lancet 2014;384:1878-88
   PubMed Web of Science ®Google Scholar
• Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011;50:1424-30
   PubMed Web of Science ®Google Scholar
• Striz I, Brabcova E, Kolesar L, et al. Cytokine networking of innate immunity cells: a potential target of therapy. Clin Sci 2014;126:593-612
   PubMed Web of Science ®Google Scholar
• Grech P, Khamashta M. Targeted therapies in systemic lupus erythematosus. Lupus 2013;22:978-86
   PubMed Web of Science ®Google Scholar
• Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008;17:394-9
   PubMed Web of Science ®Google Scholar
• Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013;65:1011-21
   PubMed Web of Science ®Google Scholar
• Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011;70:1905-13
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy and safety of sifalimumab in adults. Available from: https://clinicaltrials.gov/ct2/show/NCT01283139
   Google Scholar
• A study to evaluate safety and tolerability of IV or SC Dose of MEDI-545 in patients with systemic lupus erythematosus. Available from: https://clinicaltrials.gov/ct2/show/NCT01031836
   Google Scholar
• Kalunian K, Merrill JT, Maciuca R, et al. Efficacy and safety of rontalizumab (Anti-Interferon Alpha) in SLE Subjects with restricted immunosuppressant use: Results of A randomized, Double-blind, Placebo-controlled Phase 2 study. [abstract]. Arthritis Rheum 2012;64:2622
   Google Scholar
• Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51
   PubMed Web of Science ®Google Scholar
• Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009;48:1451-4
   PubMed Web of Science ®Google Scholar
• Cortés-Hernández J, Egri N, Vilardell-Tarrés M, et al. Etanercept in refractory lupus arthritis: An observational study. Semin Arthritis Rheum 2015;44(6):672-9
   PubMed Web of Science ®Google Scholar
• TNF Blockade with remicade in active lupus nephritis WHO class V (TRIAL). Available from: https://clinicaltrials.gov/ct2/show/NCT00368264
   Google Scholar
• Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010;62:542-52
   PubMed Web of Science ®Google Scholar
• Szepietowski JC, Nilganuwong S, Wozniacka A, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum 2013;65:2661-71
   PubMed Web of Science ®Google Scholar
• An Efficacy and safety study of CNTO 136 in patients with active lupus nephritis. Available from: https://clinicaltrials.gov/ct2/show/NCT01273389
   Google Scholar
• Li J, Wang X, Zhang F, et al. Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases. Pharmacol Ther 2013;138:441-51
   PubMed Web of Science ®Google Scholar
• Wong CK, Lit LC, Tam LS, et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008;127:385-93
   PubMed Web of Science ®Google Scholar
• He Y, Huang C, Zhang L, et al. Interleukin-21, a potential diagnostic and therapeutic target for systemic lupus erythematosus. Rheumatol Int 2014;34:1027-8
   PubMed Web of Science ®Google Scholar
• Llorente L, Richaud-Patin Y, García-Padilla C, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800
   PubMed Web of Science ®Google Scholar
• Martin DA, Boedigheimer M, Amoura Z, et al. AMG 811 (anti-IFN-gamma) treatment leads to a reduction in the whole blood IFN-signature and serum CXCL10 in Subjects with Systemic Lupus Erythematosus: Results of two Phase I Studies. The 77th Annual ACR meeting. San Diego, CA, 2013
   Google Scholar
• Vincent FB, Morand EF, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014;10:365-73
   PubMed Web of Science ®Google Scholar
• Mok MY. The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis 2010;13(1):3-11
   PubMed Web of Science ®Google Scholar
• Faurschou M, Jayne DR. Anti-B cell antibody therapies for inflammatory rheumatic diseases. Annu Rev Med 2014;65:263-78
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;17:2572-81
   Google Scholar
• Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009;18:767-76
   PubMed Web of Science ®Google Scholar
• Reddy V, Jayne D, Close D, Isenberg D. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 2013;15(Suppl 1):S2
   PubMed Web of Science ®Google Scholar
• Trial of rituximab and mycophenolate mofetil without oral steroids for lupus nephritis (RITUXILUP). Available from: https://clinicaltrials.gov/ct2/show/NCT01773616
   Google Scholar
• Synergetic B-cell immodulation in SLE (SYNBIoSe). Available from: https://clinicaltrials.gov/ct2/show/NCT02284984
   Google Scholar
• Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs 2008;9:1206-15
   PubMed Web of Science ®Google Scholar
• Mei HE, Schmidt S, Dorner T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther 2012;14(Suppl 5):S1
   PubMed Web of Science ®Google Scholar
• Al Rayes H, Touma Z. Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther 2014;17:2303-10
   Google Scholar
• Open label extension study of epratuzumab in subjects with systemic lupus erythematosus (EMBODY4). Available from: https://clinicaltrials.gov/ct2/show/NCT01408576
   Google Scholar
• Furie R, Petri M, Zamani O, et al. A Phase III, Randomized, placebo-controlled study of belimumab, A monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, Phase 3 Trial. Lancet 2011;377:721-31
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012;7:R33
   Google Scholar
• Isenberg DA. Meryl streep and the problems of clinical trials. Arthritis Rheum 2012;14:113
   Google Scholar
• Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (Sle): 52-week data (April-Sle Randomised Trial). Ann Rheum Dis 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Isenberg DA, Urowitz MB, Merril JT, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus (SLE): Results from 2 Phase III, 52 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trials. ACR annual meeting: Abstract L25, 2014
   Google Scholar
• Eli Lilly & Co. Lilly to discontinue development of tabalumab based on efficacy results in Phase III Lupus Studies. Prnewswire, Indianapolis. Available from: https://investorlillycom/releasedetailcfm?ReleaseID=874281 [Last accessed: 2 Oct.2014]
   Google Scholar
• Furie RA, Leon G, Thomas M, et al. A Phase 2, Randomised, Placebo-controlled clinical trial of blisibimod, An inhibitor of B cell activating factor, In patients with moderate-to-severe systemic lupus erythematosus, the pearl-Sc study. Ann Rheum Dis 2014;0:1-9
   Google Scholar
• CHABLIS-SC1: A study of the efficacy and safety of subcutaneous blisibimod in subjects with systemic lupus erythematosus. Available from: https://clinicaltrials.gov/ct2/show/NCT01395745
   Google Scholar
• CHABLIS-SC2: A study of the efficacy and safety of subcutaneous blisibimod in subjects with systemic lupus erythematosus with or without nephritis. Available from: https://clinicaltrials.gov/ct2/show/NCT02074020
   Google Scholar
• Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 2015;0:1-5
   Google Scholar
• Hoi A, Littlejohn G. Is there still a role for abatacept in the treatment of lupus? Expert Opin Biol Ther 2014;14:1345-50
   PubMed Web of Science ®Google Scholar
• Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;1:2913-16
   Google Scholar
• Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:3077-87
   PubMed Web of Science ®Google Scholar
• Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014;66:379-89
   PubMed Web of Science ®Google Scholar
• ACCESS Trial Group. Treatment of lupus nephritis with abatacept: The abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol 2014;66:3096-104
   PubMed Web of Science ®Google Scholar
• Treating systemic lupus erythematosus (SLE) patients with CTLA4-IgG4m (RG2077). Available from: https://clinicaltrials.gov/ct2/show/NCT00094380
   Google Scholar
• Efficacy and safety study of R935788 Tablets to treat systemic lupus erythematosus (SOLEIL). Available from: https://clinicaltrials.gov/ct2/show/NCT00752999
   Google Scholar
• Ceeraz S, Nowak EC, Burns CC, et al. Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Rheum 2014;16:469
   Google Scholar
• Shao WH, Cohen PL. The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets. Expert Rev Clin Immunol 2014;10:573-82
   PubMed Web of Science ®Google Scholar
• Markopoulou A, Kyttaris VC. Small molecules in the treatment of systemic lupus erythematosus. Clin Immunol 2013;148:359-68
   PubMed Web of Science ®Google Scholar
• Laquinimod study in systemic lupus erythematosus (SLE) patients with active lupus nephritis. Available from: https://clinicaltrials.gov/ct2/show/NCT01085097
   Google Scholar
• Barilla-LaBarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clinical immunology 2013;148:313-21
   PubMed Web of Science ®Google Scholar
• Sakthiswary R, D’Cruz D. Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore) 2014;93:e86
   PubMed Web of Science ®Google Scholar
• Guo Y, Sawalha AH, Lu Q. Epigenetics in the treatment of systemic lupus erythematosus: potential clinical application. Clin Immunol 2014;155:79-90
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of KRP203 in subacute cutaneous lupus erythematosus. Available from: https://clinicaltrials.gov/ct2/show/NCT01294774
   Google Scholar
• Tcherepanova I, Curtis M, Sale, et al. Results of a randomized placebo controlled Phase IA study of AGS-009, a humanized anti-inteferon-α monoclonal antibody in subjects with systemic lupus erythematosus. Ann Rheum Dis 2012;71:536
   Web of Science ®Google Scholar
• Goldberg A, Geppert T, Schiopu E, et al. Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther 2014;24:16
   Google Scholar
• Safety and tolerability of intravenous dose of MEDI-546 in japanese subjects with systemic lupus erythematosus. Available from: https://clinicaltrials.gov/ct2/show/NCT01559090
   Google Scholar
• A study of the efficacy and safety of MEDI-546 in systemic lupus erythematosus. Available from: https://clinicaltrials.gov/ct2/show/NCT01438489
   Google Scholar
• An open-label study to evaluate the long-term safety of MEDI-546, for the treatment of systemic lupus erythematosus, in adults. Available from: https://clinicaltrials.gov/ct2/show/NCT01753193
   Google Scholar
• Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009;48:1451-4
   PubMed Web of Science ®Google Scholar
• An investigation of safety and tolerability of NNC0114-0006 in subjects with systemic lupus erythematosus (SLE). Available from: https://clinicaltrials.gov/ct2/show/NCT01689025
   Google Scholar
• Kalunian KC, Davis JCJr, Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:3251-8
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (Anti–CD40 Ligand Antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-27
   PubMed Web of Science ®Google Scholar
• Safety study of CDP7657 in healthy volunteers and patients with systemic lupus erythematosus (SLE). Available from: https://clinicaltrials.gov/ct2/show/NCT01093911
   Google Scholar
• Safety study of CDP7657 in patients with systemic lupus erythematosus. Available from: https://clinicaltrials.gov/ct2/show/NCT01764594
   Google Scholar
• A study of AMG 557 in adults with systemic lupus erythematosus. Available from: https://clinicaltrials.gov/ct2/show/NCT00774943
   Google Scholar
• Safety and efficacy of topical R333 in patients with discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) lesions. Available from: https://clinicaltrials.gov/ct2/show/NCT01597050
   Google Scholar
• Laquinimod study in systemic lupus erythematosus (SLE) patients with active lupus arthritis. Available from: https://clinicaltrials.gov/ct2/show/NCT01085084
   Google Scholar
• Bengtsson AA, Sturfelt G, Lood C, et al. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:1579-88
   PubMed Web of Science ®Google Scholar
• Zimmer R, Scherbarth HR, Rillo OL, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 2013;72:1830-5
   PubMed Web of Science ®Google Scholar
• Ando S, Amano H, Amano E, et al. FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice. Biochem Biophys Res Commun 2010;9:804-10
   Google Scholar
• Fattah F, Isenberg D. Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. Expert Opin Biol Ther 2014;14(3):311-26
   PubMed Web of Science ®Google Scholar